MarginsXMarginsX
Home › Markets › Health Care › NSRX

Nasus Pharma Ltd. (NSRX)

NSRX trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.66
-7.32% on the day
Market cap
$31.2M
Nano cap
Revenue · 2025
$1.2B
No prior year to compare
Net income · 2025
-$5.9M
-0.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/2029039/000149315226012559/0001493152-26-012559-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerNSRX on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryNot reported by the screener
IPO year2025
SEC CIK0002029039
SEC industry codePharmaceutical Preparations
Incorporated inIsrael

Financials · 2025

LineValue
Revenue$1.2B
Net income-$5.9M
Operating income-$4.9M
Net margin-0.5%
Operating margin-0.4%
Revenue growthNo prior-year revenue to compare
Cash$1.2M
Total assets$5.0M
P/E (computed)Net income was not positive
P/S (computed)0.0×

Warning signs

Cash runway
3.0 months
$1.2M cash at December 31, 2025
Share count, 1 year
See the dilution note
Going-concern doubt
Yes
20-F filed March 25, 2026
Insider net buying, 12 months
$62K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"This has led management to conclude that there is substantial doubt about our ability to continue as a going concern."
20-F 2026-03-25
Cash and burn$1.2M cash; operating cash flow -$1.2M a quarter.Report 2025-12-31
Shares outstanding9,015,383 (2025-12-31). the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-09-18
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorBrightman Almagor Zohar & Co., Tel Aviv, IsraelPCAOB Form AP 2026-04-28
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $62K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$1.2B-$5.9M-$4.9M$1.2MNo debt tags$1.2B20-F 2026-03-25
FY 2024
2024-12-31
Not filed-$1.5M-$665K$284K$1.8MNeeds four quarters20-F 2026-03-25
FY 2023
2023-12-31
Not filed-$1.1M-$1.0M$193KNo debt tagsNeeds four quarters20-F 2026-03-25

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-09-18
Latest annual report20-F2026-03-25
Latest quarterly / interim6-K2026-11-16

Source: SEC EDGAR submissions feed, 104 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+1.8%
1 month-9.2%
3 months-10.3%
Year to date-68.6%
1 year-63.7%
From 52-week high-68.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
NNVCNanoViricides Inc.$1.24+0.81%$31.7M
NXTCNextCure Inc.$6.68+4.38%$30.6M
PMNProMIS Neurosciences Inc. Common Shares (ON)$3.31+0.61%$29.8M
SCYXSCYNEXIS Inc.$2.91-9.35%$29.0M
BCTXBriaCell Therapeutics Corp. Common Shares$3.30-2.65%$28.8M
RNTXRein Therapeutics Inc.$0.4000-27.55%$34.5M
AARDAardvark Therapeutics Inc.$1.26-5.26%$27.6M
OSTXOS Therapies Incorporated$0.6807-8.63%$35.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier